Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals' stock has been influenced by financial results and analyst recommendations. The company reported net product sales of $102.7 million in Q2 2025 and approximately $119 million in Q3 2025. Mizuho and Barclays initiated coverage with Outperform and Overweight recommendations, respectively, highlighting XDEMVY's commercialization and sales momentum. The stock reached an all-time high of $82.51 on December 24, 2025, and as of January 9, 2026, the share price was $76.88, a 45.91% increase over the past year.

Demand for Tarsus Pharmaceuticals' products, specifically XDEMVY, has shown some seasonality. The company's Q3 2025 outlook indicated softer growth due to summer vacations and holidays, a trend also observed in Q3 2024. Tarsus anticipates stronger growth in Q4 2025 and beyond, driven by direct-to-consumer campaigns and improved reimbursement.

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing eye care therapies in the United States, with plans to expand into dermatology and infectious disease prevention. Its flagship product, XDEMVY, is the first FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of investigational therapies, including TP-03 for Meibomian Gland Disease, TP-04 for Ocular Rosacea, and TP-05 for Lyme disease prevention, all currently in Phase 2a clinical trials.

Tarsus Pharmaceuticals' primary commercial focus is the United States, where XDEMVY is FDA-approved and marketed. The company plans for international launches of XDEMVY, indicating future expansion beyond the U.S. The corporate office is located in Irvine, California.

Tarsus Pharmaceuticals has cultivated a positive brand reputation due to the successful launch of XDEMVY. XDEMVY has been established as a successful eye care launch, with over 20,000 eye care professionals prescribing it as of August 2025. The company's direct-to-consumer advertising campaign has increased consumer awareness of XDEMVY, and engagement on the XDEMVY website has risen. The company's focus on unmet needs and patient care contributes to its positive image.

Tarsus Pharmaceuticals, Inc. has significant institutional ownership, with 426 institutional owners and shareholders holding 52,610,043 shares. Major institutional shareholders include BlackRock, Inc., RTW Investments, LP, and Vanguard Group Inc. Vivo Capital IX LLC is the largest individual shareholder, owning 5.71 million shares, representing 13.46% of the company.